Addiction

Pregnant individuals with opioid use disorder are commonly treated with methadone.

The receipt of DAA treatment within 1 year was 7% for patients entering the cohort in 2014, compared to 33% in 2015, 53% in 2016, and 56% in 2017.

A retrospective analysis of controlled drug dispensation shows conflicting rates of prescriptions to teenagers and young adults.

CDC investigators stated that the expansion of telehealth strategies is “urgently needed” to provide medications for opioid use disorder because it could increase retention in care and improve outcomes for OUD.

The mean daily alcohol consumption was also lower in the psilocybin group compared to the placebo group.

Reductions in prescribed benzodiazepines were especially noted in continuing prescriptions.

New comparative effectiveness data go against CDC recommendations for tapering or abruptly ending long-term opioid prescription.

After March 2020, overdose deaths not involving methadone continued to increase whereas methadone-involved overdose deaths remained stable.

According to a new report from the CDC, as fatal drug overdoses increase across the board, the Black and Indigenous communities represent a significantly greater death rates.

Data suggest continued prescribing, not initial prescribing, is linked to opioid addiction risk among exposed family members.

William F. Peacock, MD; Conar Fitton, MD; and Neel Mehta, MD, discuss the multidisciplinary approaches to selecting therapies for patients with opioid-induced constipation.

A multidisciplinary panel shares practical approaches to treating patients with opioid-induced constipation and challenges with patient communication.

Buprenorphine has shown to be effective and has the potential for widespread use to address the opioid epidemic. A subset of individuals with OUD have been acquiring it without a prescription.

An Ohio State researcher discusses a new medical center education program for navigating addiction risk in pain patients.

William F. Peacock, MD; Conar Fitton, MD; and Neel Mehta, MD, reviews the position of pharmacies in providing patients with opioid-induced constipation with the necessary medication to decrease hospitalization and cost of medication.

Experts in gastroenterology discuss the quality of life and perspective of patients with opioid-induced constipation.

Varenicline was efficacious at weeks 12, 24, and 52 of the trial compared with placebo in a smoking cessation program.

During the analysis, investigators became fascinated by how many patients entered the buprenorphine treatment program for OUD having already been taking the drug without a prescription.

William F. Peacock, MD; Conar Fitton, MD; and Neel Mehta, MD, explore the importance of early intervention and the overall challenges of ensuring that patients receive appropriate care for opioid-induced constipation.

A multidisciplinary panel discusses the presentation, frequency, and burden of opioid-induced constipation.

Dr William F. Peacock shares clinical pearls for the management of opioid-induced constipation.

An expert in emergency medicine shares his thoughts on the patient population inclusion criteria study designs when investigating treatment efficacy in patients with opioid-induced constipation.

William F. Peacock, MD, discusses real-world implications with opioid-induced constipation and comments on unmet needs in treating patients.

Dr William F. Peacock provides insight on the economic burden of opioid-induced constipation management strategies, highlighting the impact of hospitalization rates and prescription costs.

An expert in emergency medicine comments on the adverse event profile and concomitant use considerations with the administration of methylnaltrexone in patients suffering from opioid-induced constipation.

Intravenous opioid use for VOC decreased by 52% in inpatient services between 2017-2018, while oral opioid use increased.

While young adults may be resistant to drinking interventions, improving sleep behavior can indirectly reduce hazardous drinking.

Dr William F. Peacock reviews key highlights and clinical implications from the post hoc analysis of a single dose of methylnaltrexone in patients suffering from opioid-induced constipation.

William F. Peacock, MD, provides an overview of opioid induced constipation and reviews the current treatment landscape and management strategies.

Since the delivery of these medications were disrupted during the pandemic, members of racial and ethnic minority groups experienced an increased risk of opioid overdose, compared with White individuals.